Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Addition of liraglutide to overweight patients with type 2 diabetes treated with multiple daily insulin injections (MDI) with inadequate glycaemic control

Trial Profile

Addition of liraglutide to overweight patients with type 2 diabetes treated with multiple daily insulin injections (MDI) with inadequate glycaemic control

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 13 Jun 2017 Results assessing factors associated with HbA1c and weight changes, presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top